Theralase Technologies Inc. V.TLT

RE:RE:RE:RE:2 year CR?

[CancerSlayer]

DJDawg wrote:
Thanks Eog! Your posts are so informative.

I think that oncology does not have too many one and done chemo protocols in general. Many are induction followed by maintenance. As such I think that they have gotten lulled into calling the CR and DOR from the first sign that cancer cannot be found. Not finding it doesn't mean its not there. I think this carried over to NMIBC which is why all these competitors are showing CR and DOR that are quite good at 12 m. If the language changed to DOR from last treatment intervention then it would be so much more impressive to the world what ruvidar can do.

Well said...

Makes our one or two-and-done option that much more attractive from a treatment burden/side effect standpoint, especially when considering the possibility of adminitering a re-treatment(s) with our tech.  

Re: the recent N803 + BCG combo trial, it was interesting to see the number/type of treatments that were needed for this combo therapy to achieve its results.  Of note, the 58/82 patients who were CR, 13 (22%) required "re-induction" (six additional weekly doses).  

Such treatment-intensive protocols may help get you to a CR, but they may also run the risk of selecting for a more aggressive/recurrent cancer due to a given cancer's heterogeneity....so more isn't always better, which can explain the drop-off in the DOR after 12+ months.  Less can certainly be as (or more) effective in terms of both CR & DOR when using the right treatment/tech type & dose.

Our goose is about to lay a golden egg.  Always apprecite your input/analysis.  Good luck...